Drug Trial Radar · NCT07835243
A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
Mar 2, 2027
Study completion Mar 2, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single subcutaneous (SC) dose of pegozafermin administered in the abdomen, thigh, or upper arm in healthy participants.
Conditions
- Healthy Volunteers
Interventions
PegozaferminDrug
Pergozafermin will be administered as specified in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Serum Concentration (Cmax) of PegozaferminTime frame: From predose on Day 1 up to Day 22
- Area Under the Serum Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUClast) of PegozaferminTime frame: From predose on Day 1 up to Day 22
- Area Under the Serum Concentration-Time Curve Extrapolated to Infinity (AUCinf) of PegozaferminTime frame: From predose on Day 1 up to Day 22
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.